Components:
Donepezil
Donepezil
Method of action:
Anticholinesterase, Lipid Modifying Agents, M-N-Cholinomimetic, Psychoanaleptics
Anticholinesterase, Lipid Modifying Agents, M-N-Cholinomimetic, Psychoanaleptics
More... Hide...
Available in countries
See all
close

Name of the medicinal product

A Rui Si

Qualitative and quantitative composition

Donepezil

Therapeutic indications

The information provided in Therapeutic indications of A Rui Si is based on data of another medicine with exactly the same composition as the A Rui Si of the medicine (Donepezil). Be careful and be sure to specify the information on the section Therapeutic indications in the instructions to the drug A Rui Si directly from the package or from the pharmacist at the pharmacy.
more... close
Coated tablet; Film-coated tablet; Orodispersible tablet
Substance-powder

A Rui Si EVESS orodispersible tablets are indicated for the symptomatic treatment of mild to moderately severe Alzheimer's dementia.

Donepezil tablets are indicated for the symptomatic treatment of mild to moderately severe Alzheimer's dementia.

Dosage (Posology) and method of administration

The information provided in Dosage (Posology) and method of administration of A Rui Si is based on data of another medicine with exactly the same composition as the A Rui Si of the medicine (Donepezil). Be careful and be sure to specify the information on the section Dosage (Posology) and method of administration in the instructions to the drug A Rui Si directly from the package or from the pharmacist at the pharmacy.
more... close
Coated tablet; Film-coated tablet; Orodispersible tablet
Substance-powder

Posology

Adults/Elderly people

Treatment is initiated at 5 mg/day (once-a-day dosing). The 5 mg/day dose should be maintained for at least one month in order to allow the earliest clinical responses to treatment to be assessed and to allow steady-state concentrations of donepezil hydrochloride to be achieved. Following a one-month clinical assessment of treatment at 5 mg/day, the dose of A Rui Si EVESS can be increased to 10 mg/day (once-a-day dosing). The maximum recommended daily dose is 10 mg. Doses greater than 10 mg/day have not been studied in clinical trials.

Treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer's dementia. Diagnosis should be made according to accepted guidelines (e.g. DSM IV, ICD 10). Therapy with donepezil should only be started if a caregiver is available who will regularly monitor drug intake for the patient. Maintenance treatment can be continued for as long as a therapeutic benefit for the patient exists. Therefore, the clinical benefit of donepezil should be reassessed on a regular basis. Discontinuation should be considered when evidence of a therapeutic effect is no longer present. Individual response to donepezil cannot be predicted.

Upon discontinuation of treatment, a gradual abatement of the beneficial effects of A Rui Si EVESS is seen.

Paediatric population

A Rui Si EVESS is not recommended for use in children and adolescents below 18 years of age.

Patients with renal and hepatic impairment

A similar dose schedule can be followed for patients with renal impairment, as clearance of donepezil hydrochloride is not affected by this condition.

Due to possible increased exposure in mild to moderate hepatic impairment , dose escalation should be performed according to individual tolerability. There are no data for patients with severe hepatic impairment.

Method of administration

A Rui Si EVESS should be taken orally, in the evening, just prior to retiring. The tablet should be placed on the tongue and allowed to disintegrate before swallowing with or without water, according to patient preference.

Adults/Elderly:

Treatment is initiated at 5 mg/day (once-a-day dosing). Donepezil should be taken orally, in the evening, just prior to retiring. The 5 mg/day dose should be maintained for at least one month in order to allow the earliest clinical responses to treatment to be assessed and to allow steady-state concentrations of A Rui Si to be achieved. Following a one-month clinical assessment of treatment at 5 mg/day, the dose of Donepezil can be increased to 10 mg/day (once-a-day dosing). The maximum recommended daily dose is 10 mg. Doses greater than 10 mg/day have not been studied in clinical trials.

Treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer's dementia. Diagnosis should be made according to accepted guidelines (e.g. DSM IV, ICD 10). Therapy with donepezil should only be started if a caregiver is available who will regularly monitor drug intake for the patient. Maintenance treatment can be continued for as long as a therapeutic benefit for the patient exists. Therefore, the clinical benefit of donepezil should be reassessed on a regular basis. Discontinuation should be considered when evidence of a therapeutic effect is no longer present. Individual response to donepezil cannot be predicted.

Upon discontinuation of treatment, a gradual abatement of the beneficial effects of Donepezil is seen.

Renal and hepatic impairment:

A similar dose schedule can be followed for patients with renal impairment, as clearance of A Rui Si is not affected by this condition.

Due to possible increased exposure in mild to moderate hepatic impairment , dose escalation should be performed according to individual tolerability. There are no data for patients with severe hepatic impairment.

Children:

Donepezil is not recommended for use in children.

Contraindications

The information provided in Contraindications of A Rui Si is based on data of another medicine with exactly the same composition as the A Rui Si of the medicine (Donepezil). Be careful and be sure to specify the information on the section Contraindications in the instructions to the drug A Rui Si directly from the package or from the pharmacist at the pharmacy.
more... close
Coated tablet; Film-coated tablet; Orodispersible tablet
Substance-powder
<

Donepezil is contraindicated in patients with a known hypersensitivity to A Rui Si, piperidine derivatives, or to any excipients used in the formulation.

Special warnings and precautions for use

The information provided in Special warnings and precautions for use of A Rui Si is based on data of another medicine with exactly the same composition as the A Rui Si of the medicine (Donepezil). Be careful and be sure to specify the information on the section Special warnings and precautions for use in the instructions to the drug A Rui Si directly from the package or from the pharmacist at the pharmacy.
more... close
Coated tablet; Film-coated tablet; Orodispersible tablet
Substance-powder

The use of A Rui Si EVESS in patients with severe Alzheimer's dementia, other types of dementia or other types of memory impairment (e.g., age-related cognitive decline), has not been investigated.

Anaesthesia

A Rui Si EVESS as a cholinesterase inhibitor, is likely to exaggerate succinylcholine-type muscle relaxation during anaesthesia.

Cardiovascular Conditions

Because of their pharmacological action, cholinesterase inhibitors may have vagotonic effects on heart rate (e.g. bradycardia). The potential for this action may be particularly important to patients with “sick sinus syndrome” or other supraventricular cardiac conduction conditions, such as sinoatrial or atrioventricular block.

There have been reports of syncope and seizures. In investigating such patients the possibility of heart block or long sinusal pauses should be considered.

Gastrointestinal Conditions

Patients at increased risk for developing ulcers, e.g. those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs), should be monitored for symptoms. However, the clinical studies with A Rui Si EVESS showed no increase, relative to placebo, in the incidence of either peptic ulcer disease or gastrointestinal bleeding.

Genitourinary

Although not observed in clinical trials of A Rui Si EVESS, cholinomimetics may cause bladder outflow obstruction.

Neurological Conditions

Seizures: Cholinomimetics are believed to have some potential to cause generalised convulsions. However, seizure activity may also be a manifestation of Alzheimer's disease.

Cholinomimetics may have the potential to exacerbate or induce extrapyramidal symptoms.

Neuroleptic Malignant Syndrome (NMS)

NMS, a potentially life-threatening condition characterised by hyperthermia, muscle rigidity, autonomic instability, altered consciousness and elevated serum creatine phosphokinase levels, has been reported to occur very rarely in association with donepezil, particularly in patients also receiving concomitant antipsychotics. Additional signs may include myoglobinuria (rhabdomyolysis) and acute renal failure. If a patient develops signs and symptoms indicative of NMS, or presents with unexplained high fever without additional clinical manifestations of NMS, treatment should be discontinued.

Pulmonary Conditions

Because of their cholinomimetic actions, cholinesterase inhibitors should be prescribed with care to patients with a history of asthma or obstructive pulmonary disease.

The administration of A Rui Si EVESS concomitantly with other inhibitors of acetylcholinesterase, agonists or antagonists of the cholinergic system should be avoided.

Severe Hepatic Impairment

There are no data for patients with severe hepatic impairment.

Mortality in Vascular Dementia Clinical Trials

Three clinical trials of 6 months duration were conducted studying individuals meeting the NINDS-AIREN criteria for probable or possible vascular dementia (VaD). The NINDS-AIREN criteria are designed to identify patients whose dementia appears to be due solely to vascular causes and to exclude patients with Alzheimer's disease. In the first study, the mortality rates were 2/198 (1.0%) on donepezil hydrochloride 5 mg, 5/206 (2.4%) on donepezil hydrochloride 10 mg and 7/199 (3.5%) on placebo. In the second study, the mortality rates were 4/208 (1.9%) on donepezil hydrochloride 5 mg, 3/215 (1.4%) on donepezil hydrochloride 10 mg and 1/193 (0.5%) on placebo. In the third study, the mortality rates were 11/648 (1.7%) on donepezil hydrochloride 5 mg and 0/326 (0%) on placebo. The mortality rate for the three VaD studies combined in the donepezil hydrochloride group (1.7%) was numerically higher than in the placebo group (1.1%), however, this difference was not statistically significant. The majority of deaths in patients taking either donepezil hydrochloride or placebo appear to result from various vascular related causes, which could be expected in this elderly population with underlying vascular disease. An analysis of all serious non-fatal and fatal vascular events showed no difference in the rate of occurrence in the donepezil hydrochloride group relative to placebo.

In pooled Alzheimer's disease studies (n=4146), and when these Alzheimer's disease studies were pooled with other dementia studies including the vascular dementia studies (total n=6888), the mortality rate in the placebo groups numerically exceeded that in the donepezil hydrochloride groups.

The use of Donepezil in patients with severe Alzheimer's dementia, other types of dementia or other types of memory impairment (e.g., age-related cognitive decline), has not been investigated.

Anaesthesia: Donepezil, as a cholinesterase inhibitor, is likely to exaggerate succinylcholine-type muscle relaxation during anaesthesia.

Cardiovascular Conditions: Because of their pharmacological action, cholinesterase inhibitors may have vagotonic effects on heart rate (e.g., bradycardia). The potential for this action may be particularly important to patients with "sick sinus syndrome" or other supraventricular cardiac conduction conditions, such as sinoatrial or atrioventricular block.

There have been reports of syncope and seizures. In investigating such patients the possibility of heart block or long sinusal pauses should be considered.

Gastrointestinal Conditions: Patients at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs), should be monitored for symptoms. However, the clinical studies with Donepezil showed no increase, relative to placebo, in the incidence of either peptic ulcer disease or gastrointestinal bleeding.

Genitourinary: Although not observed in clinical trials of Donepezil, cholinomimetics may cause bladder outflow obstruction.

Neurological Conditions: Seizures: Cholinomimetics are believed to have some potential to cause generalised convulsions. However, seizure activity may also be a manifestation of Alzheimer's Disease.

Cholinomimetics may have the potential to exacerbate or induce extrapyramidal symptoms

Neuroleptic Malignant Syndrome (NMS): NMS, a potentially life-threatening condition characterised by hyperthermia, muscle rigidity, autonomic instability, altered consciousness and elevated serum creatine phosphokinase levels, has been reported to occur very rarely in association with donepezil, particularly in patients also receiving concomitant antipsychotics. Additional signs may include myoglobinuria (rhabdomyolysis) and acute renal failure. If a patient develops signs and symptoms indicative of NMS, or presents with unexplained high fever without additional clinical manifestations of NMS, treatment should be discontinued.

Pulmonary Conditions: Because of their cholinomimetic actions, cholinesterase inhibitors should be prescribed with care to patients with a history of asthma or obstructive pulmonary disease.

The administeration of Donepezil concomitantly with other inhibitors of acetylcholinesterase, agonists or antagonists of the cholinergic system should be avoided.

Severe Hepatic Impairment: There are no data for patients with severe hepatic impairment.

This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Mortality in Vascular Dementia Clinical Trials

Three clinical trials of 6 months duration were conducted studying individuals meeting the NINDS-AIREN criteria for probable or possible vascular dementia (VaD). The NINDS-AIREN criteria are designed to identify patients whose dementia appears to be due solely to vascular causes and to exclude patients with Alzheimer's disease. In the first study, the mortality rates were 2/198 (1.0%) on A Rui Si 5 mg, 5/206 (2.4%) on A Rui Si 10 mg and 7/199 (3.5%) on placebo. In the second study, the mortality rates were 4/208 (1.9%) on A Rui Si 5 mg, 3/215 (1.4%) on A Rui Si 10 mg and 1/193 (0.5%) on placebo. In the third study, the mortality rates were 11/648 (1.7%) on A Rui Si 5 mg and 0/326 (0%) on placebo. The mortality rate for the three VaD studies combined in the A Rui Si group (1.7%) was numerically higher than in the placebo group (1.1%), however, this difference was not statistically significant. The majority of deaths in patients taking either A Rui Si or placebo appear to result from various vascular related causes, which could be expected in this elderly population with underlying vascular disease. An analysis of all serious non-fatal and fatal vascular events showed no difference in the rate of occurrence in the A Rui Si group relative to placebo.

In pooled Alzheimer's disease studies (n=4146), and when these Alzheimer's disease studies were pooled with other dementia studies including the vascular dementia studies (total n=6888), the mortality rate in the placebo groups numerically exceeded that in the A Rui Si groups.

Effects on ability to drive and use machines

The information provided in Effects on ability to drive and use machines of A Rui Si is based on data of another medicine with exactly the same composition as the A Rui Si of the medicine (Donepezil). Be careful and be sure to specify the information on the section Effects on ability to drive and use machines in the instructions to the drug A Rui Si directly from the package or from the pharmacist at the pharmacy.
more... close
Coated tablet; Film-coated tablet; Orodispersible tablet
Substance-powder

Donepezil has minor or moderate influence on the ability to drive and use machines.

Dementia may cause impairment of driving performance or compromise the ability to use machinery. Furthermore, donepezil can induce fatigue, dizziness and muscle cramps, mainly when initiating or increasing the dose. The treating physician should routinely evaluate the ability of patients on donepezil to continue driving or operating complex machines.

Donepezil has minor or moderate influence on the ability to drive and use machines.

Dementia may cause impairment of driving performance or compromise the ability to use machinery. Furthermore, donepezil can induce fatigue, dizziness and muscle cramps, mainly when initiating or increasing the dose. The treating physician should routinely evaluate the ability of patients on donepezil to continue driving or operating complex machines.

Undesirable effects

The information provided in Undesirable effects of A Rui Si is based on data of another medicine with exactly the same composition as the A Rui Si of the medicine (Donepezil). Be careful and be sure to specify the information on the section Undesirable effects in the instructions to the drug A Rui Si directly from the package or from the pharmacist at the pharmacy.
more... close
Coated tablet; Film-coated tablet; Orodispersible tablet
Substance-powder

The most common adverse events are diarrhoea, muscle cramps, fatigue, nausea, vomiting and insomnia.

Adverse reactions reported as more than an isolated case are listed below, by system organ class and by frequency. Frequencies are defined as: very common (≥ 1/10) common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to 1/100), rare (≥ 1/10,000 to 1/1,000); very rare (< 1/10,000) and not known (cannot be estimated from available data).

System Organ Class

Very Common

Common

Uncommon

Rare

Very Rare

Infections and infestations

Common cold

Metabolism and nutrition disorders

Anorexia

Psychiatric disorders

Hallucinations**

Agitation**

Aggressive behaviour**

Abnormal dreams and Nightmares**

Nervous system disorders

Syncope*

Dizziness

Insomnia

Seizure*

Extrapyramidal symptoms

Neuroleptic malignant syndrome

Cardiac disorders

Bradycardia

Sino-atrial block

Atrioventricular block

Gastrointestinal disorders

Diarrhoea

Nausea

Vomiting

Abdominal disturbance

Gastrointestinal haemorrhage

Gastric and duodenal ulcers

Salivary hypersecretion

Hepato-biliary disorders

Liver dysfunction including hepatitis***

Skin and subcutaneous tissue disorders

Rash

Pruritis

Musculoskeletal, connective tissue and bone disorders

Muscle cramps

Rhabdomyolysis****

Renal and urinary disorders

Urinary incontinence

General disorders and administration site conditions

Headache

Fatigue

Pain

Investigations

Minor increase in serum concentration of muscle creatine kinase

Injury and poisoning

Accident

* In investigating patients for syncope or seizure the possibility of heart block or long sinusal pauses should be considered .

** Reports of hallucinations, abnormal dreams, nightmares, agitation and aggressive behaviour have resolved on dose-reduction or discontinuation of treatment.

*** In cases of unexplained liver dysfunction, withdrawal of A Rui Si EVESS should be considered.

**** Rhabdomyolysis has been reported to occur independently of Neuroleptic Malignant syndrome and in close temporal association with donepezil initiation or dose increase.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

The most common adverse events are diarrhoea, muscle cramps, fatigue, nausea, vomiting and insomnia.

Adverse reactions reported as more than an isolated case are listed below, by system organ class and by frequency. Frequencies are defined as: very common (> 1/10) common (> 1/100, < 1/10), uncommon (> 1/1,000, < 1/100), rare (> 1/10,000, < 1/1,000); very rare (< 1/10000) and not known (cannot be estimated from available data).

System Organ Class

Very Common

Common

Uncommon

Rare

Very Rare

Infections and infestations

Common cold

Metabolism and nutrition disorders

Anorexia

Psychiatric disorders

Hallucinations**

Agitation**

Aggressive behaviour**

Abnormal dreams and Nightmares**

Nervous system disorders

Syncope*

Dizziness

Insomnia

Seizure*

Extrapyramidal symptoms

Neuroleptic malignant syndrome

Cardiac disorders

Bradycardia

Sino-atrial block

Atrioventricular block

Gastrointestinal disorders

Diarrhoea

Nausea

Vomiting

Abdominal disturbance

Gastrointestinal haemorrhage

Gastric and duodenal ulcers

Hepato-biliary disorders

Liver dysfunction including hepatitis***

Skin and subcutaneous tissue disorders

Rash

Pruritis

Musculoskeletal, connective tissue and bone disorders

Muscle cramps

Rhabdomyolysis#

Renal and urinary disorders

Urinary incontinence

General disorders and administration site conditions

Headache

Fatigue

Pain

Investigations

Minor increase in serum concentration of muscle creatine kinase

Injury and poisoning

Accident

*In investigating patients for syncope or seizure the possibility of heart block or long sinusal pauses should be considered

**Reports of hallucinations, abnormal dreams, nightmares, agitation and aggressive behaviour have resolved on dose-reduction or discontinuation of treatment.

***In cases of unexplained liver dysfunction, withdrawal of Donepezil should be considered.

# Rhabdomyolysis has been reported to occur independently of neuroleptic malignant syndrome and in close temporal association with donepezil initiation or dose increase.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard.

Overdose

The information provided in Overdose of A Rui Si is based on data of another medicine with exactly the same composition as the A Rui Si of the medicine (Donepezil). Be careful and be sure to specify the information on the section Overdose in the instructions to the drug A Rui Si directly from the package or from the pharmacist at the pharmacy.
more... close
Coated tablet; Film-coated tablet; Orodispersible tablet
Substance-powder

The estimated median lethal dose of donepezil hydrochloride following administration of a single oral dose in mice and rats is 45 and 32 mg/kg, respectively, or approximately 225 and 160 times the maximum recommended human dose of 10 mg per day. Dose-related signs of cholinergic stimulation were observed in animals and included reduced spontaneous movement, prone position, staggering gait, lacrimation, clonic convulsions, depressed respiration, salivation, miosis, fasciculation and lower body surface temperature.

Overdosage with cholinesterase inhibitors can result in cholinergic crisis characterised by severe nausea, vomiting, salivation, sweating, bradycardia, hypotension, respiratory depression, collapse and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved.

As in any case of overdose, general supportive measures should be utilised. Tertiary anticholinergics such as atropine may be used as an antidote for A Rui Si EVESS overdosage. Intravenous atropine sulphate titrated to effect is recommended: an initial dose of 1.0 to 2.0 mg IV with subsequent doses based upon clinical response. Atypical responses in blood pressure and heart rate have been reported with other cholinomimetics when co-administered with quaternary anticholinergics such as glycopyrrolate. It is not known whether donepezil hydrochloride and/or its metabolites can be removed by dialysis (haemodialysis, peritoneal dialysis, or haemofiltration).

The estimated median lethal dose of A Rui Si following administration of a single oral dose in mice and rats is 45 and 32 mg/kg, respectively, or approximately 225 and 160 times the maximum recommended human dose of 10 mg per day. Dose-related signs of cholinergic stimulation were observed in animals and included reduced spontaneous movement, prone position, staggering gait, lacrimation, clonic convulsions, depressed respiration, salivation, miosis, fasciculation and lower body surface temperature.

Overdosage with cholinesterase inhibitors can result in cholinergic crisis characterized by severe nausea, vomiting, salivation, sweating, bradycardia, hypotension, respiratory depression, collapse and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved.

As in any case of overdose, general supportive measures should be utilised. Tertiary anticholinergics such as atropine may be used as an antidote for Donepezil overdosage. Intravenous atropine sulphate titrated to effect is recommended: an initial dose of 1.0 to 2.0 mg IV with subsequent doses based upon clinical response. Atypical responses in blood pressure and heart rate have been reported with other cholinomimetics when co-administered with quaternary anticholinergics such as glycopyrrolate. It is not known whether A Rui Si and/or its metabolites can be removed by dialysis (hemodialysis, peritoneal dialysis, or hemofiltration).

Pharmacodynamic properties

The information provided in Pharmacodynamic properties of A Rui Si is based on data of another medicine with exactly the same composition as the A Rui Si of the medicine (Donepezil). Be careful and be sure to specify the information on the section Pharmacodynamic properties in the instructions to the drug A Rui Si directly from the package or from the pharmacist at the pharmacy.
more... close
Coated tablet; Film-coated tablet; Orodispersible tablet
Substance-powder

Pharmacotherapeutic group: anti-dementia drugs; anticholinesterase; ATC-code N06DA02.

Mechanism of action

Donepezil hydrochloride is a specific and reversible inhibitor of acetylcholinesterase, the predominant cholinesterase in the brain. Donepezil hydrochloride is in vitro over 1000 times more potent an inhibitor of this enzyme than of butyrylcholinesterase, an enzyme that is present mainly outside the central nervous system.

Alzheimer's Dementia

In patients with Alzheimer's Dementia participating in clinical trials, administration of single daily doses of 5 mg or 10 mg of A Rui Si EVESS produced steady-state inhibition of acetylcholinesterase activity (measured in erythrocyte membranes) of 63.6% and 77.3%, respectively when measured post dose. The inhibition of acetylcholinesterase (AChE) in red blood cells by donepezil hydrochloride has been shown to correlate to changes in ADAS-cog, a sensitive scale that examines selected aspects of cognition. The potential for donepezil hydrochloride to alter the course of the underlying neuropathology has not been studied. Thus A Rui Si EVESS cannot be considered to have any effect on the progress of the disease.

Efficacy of treatment of Alzheimer's Dementia with A Rui Si EVESS has been investigated in four placebo-controlled trials, 2 trials of 6-month duration and 2 trials of 1-year duration.

In the 6 months clinical trial, an analysis was done at the conclusion of donepezil treatment using a combination of three efficacy criteria: the ADAS-Cog (a measure of cognitive performance), the Clinician Interview Based Impression of Change with Caregiver Input (a measure of global function) and the Activities of Daily Living Subscale of the Clinical Dementia Rating Scale (a measure of capabilities in community affairs, home and hobbies and personal care).

Patients who fulfilled the criteria listed below were considered treatment responders.

Response =

Improvement of ADAS-Cog of at least 4 points

No deterioration of CIBIC +

No Deterioration of Activities of Daily Living Subscale of the Clinical Dementia Rating Scale

% Response

Intent to Treat Population

n=365

Evaluable Population

n=352

Placebo Group

10%

10%

A Rui Si EVESS tablets 5-mg Group

18%*

18%*

A Rui Si EVESS tablets 10-mg Group

21%*

22%**

*p<0.05

**p<0.01

A Rui Si EVESS produced a dose-dependent statistically significant increase in the percentage of patients who were judged treatment responders.

The pharmacotherapeutic group: anti-dementia drugs; anticholinesterase; ATC-code N06DA02.

A Rui Si is a specific and reversible inhibitor of acetylcholinesterase, the predominant cholinesterase in the brain. A Rui Si is in vitro over 1000 times more potent an inhibitor of this enzyme than of butyrylcholinesterase, an enzyme that is present mainly outside the central nervous system.

Alzheimer's Dementia

In patients with Alzheimer's Dementia participating in clinical trials, administration of single daily doses of 5 mg or 10 mg of Donepezil produced steady-state inhibition of acetylcholinesterase activity (measured in erythrocyte membranes) of 63.6% and 77.3%, respectively when measured post dose. The inhibition of acetylcholinesterase (AChE) in red blood cells by A Rui Si has been shown to correlate to changes in ADAS-cog, a sensitive scale which examines selected aspects of cognition. The potential for A Rui Si to alter the course of the underlying neuropathology has not been studied. Thus Donepezil can not be considered to have any effect on the progress of the disease.

Efficacy of treatment with Donepezil has been investigated in four placebo-controlled trials, 2 trials of 6-month duration and 2 trials of 1-year duration.

In the 6 months clinical trial, an analysis was done at the conclusion of donepezil treatment using a combination of three efficacy criteria: the ADAS-Cog (a measure of cognitive performance), the Clinician Interview Based Impression of Change with Caregiver Input (a measure of global function) and the Activities of Daily Living Subscale of the Clinical Dementia Rating Scale ( a measure of capabilities in community affairs, home and hobbies and personal care).

Patients who fulfilled the criteria listed below were considered treatment responders.

Response = Improvement of ADAS-Cog of at least 4 points

No deterioration of CIBIC +

No Deterioration of Activities of Daily Living Subscale of the Clinical Dementia Rating Scale

% Response

Intent to Treat Population

n = 365

Evaluable Population

n = 352

Placebo group

10%

10%

A Rui Si 5 mg group

18%*

18%*

A Rui Si 10 mg group

21%*

22%**

* p<0.05

** p<0.01

Donepezil produced a dose-dependent statistically significant increase in the percentage of patients who were judged treatment responders.

Pharmacokinetic properties

The information provided in Pharmacokinetic properties of A Rui Si is based on data of another medicine with exactly the same composition as the A Rui Si of the medicine (Donepezil). Be careful and be sure to specify the information on the section Pharmacokinetic properties in the instructions to the drug A Rui Si directly from the package or from the pharmacist at the pharmacy.
more... close
Coated tablet; Film-coated tablet; Orodispersible tablet
Substance-powder

Absorption

Maximum plasma levels are reached approximately 3 to 4 hours after oral administration. Plasma concentrations and area under the curve rise in proportion to the dose. The terminal disposition half-life is approximately 70 hours, thus, administration of multiple single-daily doses results in gradual approach to steady-state. Approximate steady-state is achieved within 3 weeks after initiation of therapy. Once at steady-state, plasma donepezil hydrochloride concentrations and the related pharmacodynamic activity show little variability over the course of the day.

Food did not affect the absorption of donepezil hydrochloride.

Distribution

Donepezil hydrochloride is approximately 95% bound to human plasma proteins. The plasma protein binding of the active metabolite 6-O-desmethyl donepezil is not known. The distribution of donepezil hydrochloride in various body tissues has not been definitively studied. However, in a mass balance study conducted in healthy male volunteers, 240 hours after the administration of a single 5 mg dose of 14C-labelled donepezil hydrochloride, approximately 28% of the label remained unrecovered. This suggests that donepezil hydrochloride and/or its metabolites may persist in the body for more than 10 days.

Biotransformation/ Elimination

Donepezil hydrochloride is both excreted in the urine intact and metabolised by the cytochrome P450 system to multiple metabolites, not all of which have been identified. Following administration of a single 5 mg dose of 14C-labelled donepezil hydrochloride, plasma radioactivity, expressed as a percent of the administered dose, was present primarily as intact donepezil hydrochloride (30%), 6-O-desmethyl donepezil (11% – only metabolite that exhibits activity similar to donepezil hydrochloride), donepezil-cis-N-oxide (9%), 5-O-desmethyl donepezil (7%) and the glucuronide conjugate of 5-O-desmethyl donepezil (3%). Approximately 57% of the total administered radioactivity was recovered from the urine (17% as unchanged donepezil), and 14.5% was recovered from the faeces, suggesting biotransformation and urinary excretion as the primary routes of elimination. There is no evidence to suggest enterohepatic recirculation of donepezil hydrochloride and/or any of its metabolites.

Plasma donepezil concentrations decline with a half-life of approximately 70 hours.

Sex, race and smoking history have no clinically significant influence on plasma concentrations of donepezil hydrochloride. The pharmacokinetics of donepezil has not been formally studied in healthy elderly subjects or in Alzheimer's or vascular dementia patients. However mean plasma levels in patients closely agreed with those of young healthy volunteers.

Patients with mild to moderate hepatic impairment had increased donepezil steady state concentrations; mean AUC by 48% and mean Cmax by 39% .

Absorption: Maximum plasma levels are reached approximately 3 to 4 hours after oral administration. Plasma concentrations and area under the curve rise in proportion to the dose. The terminal disposition half-life is approximately 70 hours, thus, administration of multiple single-daily doses results in gradual approach to steady-state. Approximate steady-state is achieved within 3 weeks after initiation of therapy. Once at steady-state, plasma A Rui Si concentrations and the related pharmacodynamic activity show little variability over the course of the day.

Food did not affect the absorption of A Rui Si.

Distribution: A Rui Si is approximately 95% bound to human plasma proteins. The plasma protein binding of the active metabolite 6-O-desmethyldonepezil is not known. The distribution of A Rui Si in various body tissues has not been definitively studied. However, in a mass balance study conducted in healthy male volunteers, 240 hours after the administration of a single 5 mg dose of 14C-labeled A Rui Si, approximately 28% of the label remained unrecovered. This suggests that A Rui Si and/or its metabolites may persist in the body for more than 10 days.

Metabolism/Excretion: A Rui Si is both excreted in the urine intact and metabolised by the cytochrome P450 system to multiple metabolites, not all of which have been identified. Following administration of a single 5 mg dose of 14C-labeled A Rui Si, plasma radioactivity, expressed as a percent of the administered dose, was present primarily as intact A Rui Si (30%), 6-O-desmethyl donepezil (11% - only metabolite that exhibits activity similar to A Rui Si), donepezil-cis-N-oxide (9%), 5-O-desmethyl donepezil (7%) and the glucuronide conjugate of 5-O-desmethyl donepezil (3%). Approximately 57% of the total administered radioactivity was recovered from the urine (17% as unchanged donepezil), and 14.5% was recovered from the faeces, suggesting biotransformation and urinary excretion as the primary routes of elimination. There is no evidence to suggest enterohepatic recirculation of A Rui Si and/or any of its metabolites.

Plasma donepezil concentrations decline with a half-life of approximately 70 hours.

Sex, race and smoking history have no clinically significant influence on plasma concentrations of A Rui Si. The pharmacokinetics of donepezil has not been formally studied in healthy elderly subjects or in Alzheimer's or vascular dementia patients. However mean plasma levels in patients closely agreed with those of young healthy volunteers.

Patients with mild to moderate hepatic impairment had increased donepezil steady state concentrations; mean AUC by 48% and mean Cmax by 39% .

Pharmacotherapeutic group

The information provided in Pharmacotherapeutic group of A Rui Si is based on data of another medicine with exactly the same composition as the A Rui Si of the medicine (Donepezil). Be careful and be sure to specify the information on the section Pharmacotherapeutic group in the instructions to the drug A Rui Si directly from the package or from the pharmacist at the pharmacy.
more... close
anti-dementia drugs; anticholinesterase; ATC-code N06DA02.

Preclinical safety data

The information provided in Preclinical safety data of A Rui Si is based on data of another medicine with exactly the same composition as the A Rui Si of the medicine (Donepezil). Be careful and be sure to specify the information on the section Preclinical safety data in the instructions to the drug A Rui Si directly from the package or from the pharmacist at the pharmacy.
more... close
Coated tablet; Film-coated tablet; Orodispersible tablet
Substance-powder

Extensive testing in experimental animals has demonstrated that this compound causes few effects other than the intended pharmacological effects consistent with its action as a cholinergic stimulator . Donepezil is not mutagenic in bacterial and mammalian cell mutation assays. Some clastogenic effects were observed in vitro at concentrations overtly toxic to the cells and more than 3000 times the steady-state plasma concentrations. No clastogenic or other genotoxic effects were observed in the mouse micronucleus model in vivo. There was no evidence of oncogenic potential in long-term carcinogenicity studies in either rats or mice.

Donepezil hydrochloride had no effect on fertility in rats, and was not teratogenic in rats or rabbits, but had a slight effect on still-births and early pup survival when administered to pregnant rats at 50 times the human dose .

Extensive testing in experimental animals has demonstrated that this compound causes few effects other than the intended pharmacological effects consistent with its action as a cholinergic stimulator . Donepezil is not mutagenic in bacterial and mammalian cell mutation assays. Some clastogenic effects were observed in vitro at concentrations overtly toxic to the cells and more than 3000 times the steady-state plasma concentrations. No clastogenic or other genotoxic effects were observed in the mouse micronucleus model in vivo. There was no evidence of oncogenic potential in long term carcinogenicity studies in either rats or mice.

A Rui Si had no effect on fertility in rats, and was not teratogenic in rats or rabbits, but had a slight effect on still births and early pup survival when administered to pregnant rats at 50 times the human dose .

Incompatibilities

The information provided in Incompatibilities of A Rui Si is based on data of another medicine with exactly the same composition as the A Rui Si of the medicine (Donepezil). Be careful and be sure to specify the information on the section Incompatibilities in the instructions to the drug A Rui Si directly from the package or from the pharmacist at the pharmacy.
more... close
Coated tablet; Film-coated tablet; Orodispersible tablet
Substance-powder

Not applicable.

Not applicable

Special precautions for disposal and other handling

The information provided in Special precautions for disposal and other handling of A Rui Si is based on data of another medicine with exactly the same composition as the A Rui Si of the medicine (Donepezil). Be careful and be sure to specify the information on the section Special precautions for disposal and other handling in the instructions to the drug A Rui Si directly from the package or from the pharmacist at the pharmacy.
more... close
Coated tablet; Film-coated tablet; Orodispersible tablet
Substance-powder

No special requirements.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Name of the medicinal product
A Rui Si
Qualitative and quantitative composition
Donepezil
Therapeutic indications
The information provided in Therapeutic indications of A Rui Si is based on data of another medicine with exactly the same composition as the A Rui Si of the medicine (Donepezil). Be careful and be sure to specify the information on the section Therapeutic indications in the instructions to the drug A Rui Si directly from the package or from the pharmacist at the pharmacy.
more... close
Coated tablet; Film-coated tablet; Orodispersible tablet
Substance-powder

A Rui Si EVESS orodispersible tablets are indicated for the symptomatic treatment of mild to moderately severe Alzheimer's dementia.

Donepezil tablets are indicated for the symptomatic treatment of mild to moderately severe Alzheimer's dementia.

Dosage (Posology) and method of administration
The information provided in Dosage (Posology) and method of administration of A Rui Si is based on data of another medicine with exactly the same composition as the A Rui Si of the medicine (Donepezil). Be careful and be sure to specify the information on the section Dosage (Posology) and method of administration in the instructions to the drug A Rui Si directly from the package or from the pharmacist at the pharmacy.
more... close
Coated tablet; Film-coated tablet; Orodispersible tablet
Substance-powder

Posology

Adults/Elderly people

Treatment is initiated at 5 mg/day (once-a-day dosing). The 5 mg/day dose should be maintained for at least one month in order to allow the earliest clinical responses to treatment to be assessed and to allow steady-state concentrations of donepezil hydrochloride to be achieved. Following a one-month clinical assessment of treatment at 5 mg/day, the dose of A Rui Si EVESS can be increased to 10 mg/day (once-a-day dosing). The maximum recommended daily dose is 10 mg. Doses greater than 10 mg/day have not been studied in clinical trials.

Treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer's dementia. Diagnosis should be made according to accepted guidelines (e.g. DSM IV, ICD 10). Therapy with donepezil should only be started if a caregiver is available who will regularly monitor drug intake for the patient. Maintenance treatment can be continued for as long as a therapeutic benefit for the patient exists. Therefore, the clinical benefit of donepezil should be reassessed on a regular basis. Discontinuation should be considered when evidence of a therapeutic effect is no longer present. Individual response to donepezil cannot be predicted.

Upon discontinuation of treatment, a gradual abatement of the beneficial effects of A Rui Si EVESS is seen.

Paediatric population

A Rui Si EVESS is not recommended for use in children and adolescents below 18 years of age.

Patients with renal and hepatic impairment

A similar dose schedule can be followed for patients with renal impairment, as clearance of donepezil hydrochloride is not affected by this condition.

Due to possible increased exposure in mild to moderate hepatic impairment , dose escalation should be performed according to individual tolerability. There are no data for patients with severe hepatic impairment.

Method of administration

A Rui Si EVESS should be taken orally, in the evening, just prior to retiring. The tablet should be placed on the tongue and allowed to disintegrate before swallowing with or without water, according to patient preference.

Adults/Elderly:

Treatment is initiated at 5 mg/day (once-a-day dosing). Donepezil should be taken orally, in the evening, just prior to retiring. The 5 mg/day dose should be maintained for at least one month in order to allow the earliest clinical responses to treatment to be assessed and to allow steady-state concentrations of A Rui Si to be achieved. Following a one-month clinical assessment of treatment at 5 mg/day, the dose of Donepezil can be increased to 10 mg/day (once-a-day dosing). The maximum recommended daily dose is 10 mg. Doses greater than 10 mg/day have not been studied in clinical trials.

Treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer's dementia. Diagnosis should be made according to accepted guidelines (e.g. DSM IV, ICD 10). Therapy with donepezil should only be started if a caregiver is available who will regularly monitor drug intake for the patient. Maintenance treatment can be continued for as long as a therapeutic benefit for the patient exists. Therefore, the clinical benefit of donepezil should be reassessed on a regular basis. Discontinuation should be considered when evidence of a therapeutic effect is no longer present. Individual response to donepezil cannot be predicted.

Upon discontinuation of treatment, a gradual abatement of the beneficial effects of Donepezil is seen.

Renal and hepatic impairment:

A similar dose schedule can be followed for patients with renal impairment, as clearance of A Rui Si is not affected by this condition.

Due to possible increased exposure in mild to moderate hepatic impairment , dose escalation should be performed according to individual tolerability. There are no data for patients with severe hepatic impairment.

Children:

Donepezil is not recommended for use in children.

Contraindications
The information provided in Contraindications of A Rui Si is based on data of another medicine with exactly the same composition as the A Rui Si of the medicine (Donepezil). Be careful and be sure to specify the information on the section Contraindications in the instructions to the drug A Rui Si directly from the package or from the pharmacist at the pharmacy.
more... close
Coated tablet; Film-coated tablet; Orodispersible tablet
Substance-powder
<

Donepezil is contraindicated in patients with a known hypersensitivity to A Rui Si, piperidine derivatives, or to any excipients used in the formulation.

Special warnings and precautions for use
The information provided in Special warnings and precautions for use of A Rui Si is based on data of another medicine with exactly the same composition as the A Rui Si of the medicine (Donepezil). Be careful and be sure to specify the information on the section Special warnings and precautions for use in the instructions to the drug A Rui Si directly from the package or from the pharmacist at the pharmacy.
more... close
Coated tablet; Film-coated tablet; Orodispersible tablet
Substance-powder

The use of A Rui Si EVESS in patients with severe Alzheimer's dementia, other types of dementia or other types of memory impairment (e.g., age-related cognitive decline), has not been investigated.

Anaesthesia

A Rui Si EVESS as a cholinesterase inhibitor, is likely to exaggerate succinylcholine-type muscle relaxation during anaesthesia.

Cardiovascular Conditions

Because of their pharmacological action, cholinesterase inhibitors may have vagotonic effects on heart rate (e.g. bradycardia). The potential for this action may be particularly important to patients with “sick sinus syndrome” or other supraventricular cardiac conduction conditions, such as sinoatrial or atrioventricular block.

There have been reports of syncope and seizures. In investigating such patients the possibility of heart block or long sinusal pauses should be considered.

Gastrointestinal Conditions

Patients at increased risk for developing ulcers, e.g. those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs), should be monitored for symptoms. However, the clinical studies with A Rui Si EVESS showed no increase, relative to placebo, in the incidence of either peptic ulcer disease or gastrointestinal bleeding.

Genitourinary

Although not observed in clinical trials of A Rui Si EVESS, cholinomimetics may cause bladder outflow obstruction.

Neurological Conditions

Seizures: Cholinomimetics are believed to have some potential to cause generalised convulsions. However, seizure activity may also be a manifestation of Alzheimer's disease.

Cholinomimetics may have the potential to exacerbate or induce extrapyramidal symptoms.

Neuroleptic Malignant Syndrome (NMS)

NMS, a potentially life-threatening condition characterised by hyperthermia, muscle rigidity, autonomic instability, altered consciousness and elevated serum creatine phosphokinase levels, has been reported to occur very rarely in association with donepezil, particularly in patients also receiving concomitant antipsychotics. Additional signs may include myoglobinuria (rhabdomyolysis) and acute renal failure. If a patient develops signs and symptoms indicative of NMS, or presents with unexplained high fever without additional clinical manifestations of NMS, treatment should be discontinued.

Pulmonary Conditions

Because of their cholinomimetic actions, cholinesterase inhibitors should be prescribed with care to patients with a history of asthma or obstructive pulmonary disease.

The administration of A Rui Si EVESS concomitantly with other inhibitors of acetylcholinesterase, agonists or antagonists of the cholinergic system should be avoided.

Severe Hepatic Impairment

There are no data for patients with severe hepatic impairment.

Mortality in Vascular Dementia Clinical Trials

Three clinical trials of 6 months duration were conducted studying individuals meeting the NINDS-AIREN criteria for probable or possible vascular dementia (VaD). The NINDS-AIREN criteria are designed to identify patients whose dementia appears to be due solely to vascular causes and to exclude patients with Alzheimer's disease. In the first study, the mortality rates were 2/198 (1.0%) on donepezil hydrochloride 5 mg, 5/206 (2.4%) on donepezil hydrochloride 10 mg and 7/199 (3.5%) on placebo. In the second study, the mortality rates were 4/208 (1.9%) on donepezil hydrochloride 5 mg, 3/215 (1.4%) on donepezil hydrochloride 10 mg and 1/193 (0.5%) on placebo. In the third study, the mortality rates were 11/648 (1.7%) on donepezil hydrochloride 5 mg and 0/326 (0%) on placebo. The mortality rate for the three VaD studies combined in the donepezil hydrochloride group (1.7%) was numerically higher than in the placebo group (1.1%), however, this difference was not statistically significant. The majority of deaths in patients taking either donepezil hydrochloride or placebo appear to result from various vascular related causes, which could be expected in this elderly population with underlying vascular disease. An analysis of all serious non-fatal and fatal vascular events showed no difference in the rate of occurrence in the donepezil hydrochloride group relative to placebo.

In pooled Alzheimer's disease studies (n=4146), and when these Alzheimer's disease studies were pooled with other dementia studies including the vascular dementia studies (total n=6888), the mortality rate in the placebo groups numerically exceeded that in the donepezil hydrochloride groups.

The use of Donepezil in patients with severe Alzheimer's dementia, other types of dementia or other types of memory impairment (e.g., age-related cognitive decline), has not been investigated.

Anaesthesia: Donepezil, as a cholinesterase inhibitor, is likely to exaggerate succinylcholine-type muscle relaxation during anaesthesia.

Cardiovascular Conditions: Because of their pharmacological action, cholinesterase inhibitors may have vagotonic effects on heart rate (e.g., bradycardia). The potential for this action may be particularly important to patients with "sick sinus syndrome" or other supraventricular cardiac conduction conditions, such as sinoatrial or atrioventricular block.

There have been reports of syncope and seizures. In investigating such patients the possibility of heart block or long sinusal pauses should be considered.

Gastrointestinal Conditions: Patients at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs), should be monitored for symptoms. However, the clinical studies with Donepezil showed no increase, relative to placebo, in the incidence of either peptic ulcer disease or gastrointestinal bleeding.

Genitourinary: Although not observed in clinical trials of Donepezil, cholinomimetics may cause bladder outflow obstruction.

Neurological Conditions: Seizures: Cholinomimetics are believed to have some potential to cause generalised convulsions. However, seizure activity may also be a manifestation of Alzheimer's Disease.

Cholinomimetics may have the potential to exacerbate or induce extrapyramidal symptoms

Neuroleptic Malignant Syndrome (NMS): NMS, a potentially life-threatening condition characterised by hyperthermia, muscle rigidity, autonomic instability, altered consciousness and elevated serum creatine phosphokinase levels, has been reported to occur very rarely in association with donepezil, particularly in patients also receiving concomitant antipsychotics. Additional signs may include myoglobinuria (rhabdomyolysis) and acute renal failure. If a patient develops signs and symptoms indicative of NMS, or presents with unexplained high fever without additional clinical manifestations of NMS, treatment should be discontinued.

Pulmonary Conditions: Because of their cholinomimetic actions, cholinesterase inhibitors should be prescribed with care to patients with a history of asthma or obstructive pulmonary disease.

The administeration of Donepezil concomitantly with other inhibitors of acetylcholinesterase, agonists or antagonists of the cholinergic system should be avoided.

Severe Hepatic Impairment: There are no data for patients with severe hepatic impairment.

This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Mortality in Vascular Dementia Clinical Trials

Three clinical trials of 6 months duration were conducted studying individuals meeting the NINDS-AIREN criteria for probable or possible vascular dementia (VaD). The NINDS-AIREN criteria are designed to identify patients whose dementia appears to be due solely to vascular causes and to exclude patients with Alzheimer's disease. In the first study, the mortality rates were 2/198 (1.0%) on A Rui Si 5 mg, 5/206 (2.4%) on A Rui Si 10 mg and 7/199 (3.5%) on placebo. In the second study, the mortality rates were 4/208 (1.9%) on A Rui Si 5 mg, 3/215 (1.4%) on A Rui Si 10 mg and 1/193 (0.5%) on placebo. In the third study, the mortality rates were 11/648 (1.7%) on A Rui Si 5 mg and 0/326 (0%) on placebo. The mortality rate for the three VaD studies combined in the A Rui Si group (1.7%) was numerically higher than in the placebo group (1.1%), however, this difference was not statistically significant. The majority of deaths in patients taking either A Rui Si or placebo appear to result from various vascular related causes, which could be expected in this elderly population with underlying vascular disease. An analysis of all serious non-fatal and fatal vascular events showed no difference in the rate of occurrence in the A Rui Si group relative to placebo.

In pooled Alzheimer's disease studies (n=4146), and when these Alzheimer's disease studies were pooled with other dementia studies including the vascular dementia studies (total n=6888), the mortality rate in the placebo groups numerically exceeded that in the A Rui Si groups.

Effects on ability to drive and use machines
The information provided in Effects on ability to drive and use machines of A Rui Si is based on data of another medicine with exactly the same composition as the A Rui Si of the medicine (Donepezil). Be careful and be sure to specify the information on the section Effects on ability to drive and use machines in the instructions to the drug A Rui Si directly from the package or from the pharmacist at the pharmacy.
more... close
Coated tablet; Film-coated tablet; Orodispersible tablet
Substance-powder

Donepezil has minor or moderate influence on the ability to drive and use machines.

Dementia may cause impairment of driving performance or compromise the ability to use machinery. Furthermore, donepezil can induce fatigue, dizziness and muscle cramps, mainly when initiating or increasing the dose. The treating physician should routinely evaluate the ability of patients on donepezil to continue driving or operating complex machines.

Donepezil has minor or moderate influence on the ability to drive and use machines.

Dementia may cause impairment of driving performance or compromise the ability to use machinery. Furthermore, donepezil can induce fatigue, dizziness and muscle cramps, mainly when initiating or increasing the dose. The treating physician should routinely evaluate the ability of patients on donepezil to continue driving or operating complex machines.

Undesirable effects
The information provided in Undesirable effects of A Rui Si is based on data of another medicine with exactly the same composition as the A Rui Si of the medicine (Donepezil). Be careful and be sure to specify the information on the section Undesirable effects in the instructions to the drug A Rui Si directly from the package or from the pharmacist at the pharmacy.
more... close
Coated tablet; Film-coated tablet; Orodispersible tablet
Substance-powder

The most common adverse events are diarrhoea, muscle cramps, fatigue, nausea, vomiting and insomnia.

Adverse reactions reported as more than an isolated case are listed below, by system organ class and by frequency. Frequencies are defined as: very common (≥ 1/10) common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to 1/100), rare (≥ 1/10,000 to 1/1,000); very rare (< 1/10,000) and not known (cannot be estimated from available data).

System Organ Class

Very Common

Common

Uncommon

Rare

Very Rare

Infections and infestations

Common cold

Metabolism and nutrition disorders

Anorexia

Psychiatric disorders

Hallucinations**

Agitation**

Aggressive behaviour**

Abnormal dreams and Nightmares**

Nervous system disorders

Syncope*

Dizziness

Insomnia

Seizure*

Extrapyramidal symptoms

Neuroleptic malignant syndrome

Cardiac disorders

Bradycardia

Sino-atrial block

Atrioventricular block

Gastrointestinal disorders

Diarrhoea

Nausea

Vomiting

Abdominal disturbance

Gastrointestinal haemorrhage

Gastric and duodenal ulcers

Salivary hypersecretion

Hepato-biliary disorders

Liver dysfunction including hepatitis***

Skin and subcutaneous tissue disorders

Rash

Pruritis

Musculoskeletal, connective tissue and bone disorders

Muscle cramps

Rhabdomyolysis****

Renal and urinary disorders

Urinary incontinence

General disorders and administration site conditions

Headache

Fatigue

Pain

Investigations

Minor increase in serum concentration of muscle creatine kinase

Injury and poisoning

Accident

* In investigating patients for syncope or seizure the possibility of heart block or long sinusal pauses should be considered .

** Reports of hallucinations, abnormal dreams, nightmares, agitation and aggressive behaviour have resolved on dose-reduction or discontinuation of treatment.

*** In cases of unexplained liver dysfunction, withdrawal of A Rui Si EVESS should be considered.

**** Rhabdomyolysis has been reported to occur independently of Neuroleptic Malignant syndrome and in close temporal association with donepezil initiation or dose increase.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

The most common adverse events are diarrhoea, muscle cramps, fatigue, nausea, vomiting and insomnia.

Adverse reactions reported as more than an isolated case are listed below, by system organ class and by frequency. Frequencies are defined as: very common (> 1/10) common (> 1/100, < 1/10), uncommon (> 1/1,000, < 1/100), rare (> 1/10,000, < 1/1,000); very rare (< 1/10000) and not known (cannot be estimated from available data).

System Organ Class

Very Common

Common

Uncommon

Rare

Very Rare

Infections and infestations

Common cold

Metabolism and nutrition disorders

Anorexia

Psychiatric disorders

Hallucinations**

Agitation**

Aggressive behaviour**

Abnormal dreams and Nightmares**

Nervous system disorders

Syncope*

Dizziness

Insomnia

Seizure*

Extrapyramidal symptoms

Neuroleptic malignant syndrome

Cardiac disorders

Bradycardia

Sino-atrial block

Atrioventricular block

Gastrointestinal disorders

Diarrhoea

Nausea

Vomiting

Abdominal disturbance

Gastrointestinal haemorrhage

Gastric and duodenal ulcers

Hepato-biliary disorders

Liver dysfunction including hepatitis***

Skin and subcutaneous tissue disorders

Rash

Pruritis

Musculoskeletal, connective tissue and bone disorders

Muscle cramps

Rhabdomyolysis#

Renal and urinary disorders

Urinary incontinence

General disorders and administration site conditions

Headache

Fatigue

Pain

Investigations

Minor increase in serum concentration of muscle creatine kinase

Injury and poisoning

Accident

*In investigating patients for syncope or seizure the possibility of heart block or long sinusal pauses should be considered

**Reports of hallucinations, abnormal dreams, nightmares, agitation and aggressive behaviour have resolved on dose-reduction or discontinuation of treatment.

***In cases of unexplained liver dysfunction, withdrawal of Donepezil should be considered.

# Rhabdomyolysis has been reported to occur independently of neuroleptic malignant syndrome and in close temporal association with donepezil initiation or dose increase.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard.

Overdose
The information provided in Overdose of A Rui Si is based on data of another medicine with exactly the same composition as the A Rui Si of the medicine (Donepezil). Be careful and be sure to specify the information on the section Overdose in the instructions to the drug A Rui Si directly from the package or from the pharmacist at the pharmacy.
more... close
Coated tablet; Film-coated tablet; Orodispersible tablet
Substance-powder

The estimated median lethal dose of donepezil hydrochloride following administration of a single oral dose in mice and rats is 45 and 32 mg/kg, respectively, or approximately 225 and 160 times the maximum recommended human dose of 10 mg per day. Dose-related signs of cholinergic stimulation were observed in animals and included reduced spontaneous movement, prone position, staggering gait, lacrimation, clonic convulsions, depressed respiration, salivation, miosis, fasciculation and lower body surface temperature.

Overdosage with cholinesterase inhibitors can result in cholinergic crisis characterised by severe nausea, vomiting, salivation, sweating, bradycardia, hypotension, respiratory depression, collapse and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved.

As in any case of overdose, general supportive measures should be utilised. Tertiary anticholinergics such as atropine may be used as an antidote for A Rui Si EVESS overdosage. Intravenous atropine sulphate titrated to effect is recommended: an initial dose of 1.0 to 2.0 mg IV with subsequent doses based upon clinical response. Atypical responses in blood pressure and heart rate have been reported with other cholinomimetics when co-administered with quaternary anticholinergics such as glycopyrrolate. It is not known whether donepezil hydrochloride and/or its metabolites can be removed by dialysis (haemodialysis, peritoneal dialysis, or haemofiltration).

The estimated median lethal dose of A Rui Si following administration of a single oral dose in mice and rats is 45 and 32 mg/kg, respectively, or approximately 225 and 160 times the maximum recommended human dose of 10 mg per day. Dose-related signs of cholinergic stimulation were observed in animals and included reduced spontaneous movement, prone position, staggering gait, lacrimation, clonic convulsions, depressed respiration, salivation, miosis, fasciculation and lower body surface temperature.

Overdosage with cholinesterase inhibitors can result in cholinergic crisis characterized by severe nausea, vomiting, salivation, sweating, bradycardia, hypotension, respiratory depression, collapse and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved.

As in any case of overdose, general supportive measures should be utilised. Tertiary anticholinergics such as atropine may be used as an antidote for Donepezil overdosage. Intravenous atropine sulphate titrated to effect is recommended: an initial dose of 1.0 to 2.0 mg IV with subsequent doses based upon clinical response. Atypical responses in blood pressure and heart rate have been reported with other cholinomimetics when co-administered with quaternary anticholinergics such as glycopyrrolate. It is not known whether A Rui Si and/or its metabolites can be removed by dialysis (hemodialysis, peritoneal dialysis, or hemofiltration).

Pharmacodynamic properties
The information provided in Pharmacodynamic properties of A Rui Si is based on data of another medicine with exactly the same composition as the A Rui Si of the medicine (Donepezil). Be careful and be sure to specify the information on the section Pharmacodynamic properties in the instructions to the drug A Rui Si directly from the package or from the pharmacist at the pharmacy.
more... close
Coated tablet; Film-coated tablet; Orodispersible tablet
Substance-powder

Pharmacotherapeutic group: anti-dementia drugs; anticholinesterase; ATC-code N06DA02.

Mechanism of action

Donepezil hydrochloride is a specific and reversible inhibitor of acetylcholinesterase, the predominant cholinesterase in the brain. Donepezil hydrochloride is in vitro over 1000 times more potent an inhibitor of this enzyme than of butyrylcholinesterase, an enzyme that is present mainly outside the central nervous system.

Alzheimer's Dementia

In patients with Alzheimer's Dementia participating in clinical trials, administration of single daily doses of 5 mg or 10 mg of A Rui Si EVESS produced steady-state inhibition of acetylcholinesterase activity (measured in erythrocyte membranes) of 63.6% and 77.3%, respectively when measured post dose. The inhibition of acetylcholinesterase (AChE) in red blood cells by donepezil hydrochloride has been shown to correlate to changes in ADAS-cog, a sensitive scale that examines selected aspects of cognition. The potential for donepezil hydrochloride to alter the course of the underlying neuropathology has not been studied. Thus A Rui Si EVESS cannot be considered to have any effect on the progress of the disease.

Efficacy of treatment of Alzheimer's Dementia with A Rui Si EVESS has been investigated in four placebo-controlled trials, 2 trials of 6-month duration and 2 trials of 1-year duration.

In the 6 months clinical trial, an analysis was done at the conclusion of donepezil treatment using a combination of three efficacy criteria: the ADAS-Cog (a measure of cognitive performance), the Clinician Interview Based Impression of Change with Caregiver Input (a measure of global function) and the Activities of Daily Living Subscale of the Clinical Dementia Rating Scale (a measure of capabilities in community affairs, home and hobbies and personal care).

Patients who fulfilled the criteria listed below were considered treatment responders.

Response =

Improvement of ADAS-Cog of at least 4 points

No deterioration of CIBIC +

No Deterioration of Activities of Daily Living Subscale of the Clinical Dementia Rating Scale

% Response

Intent to Treat Population

n=365

Evaluable Population

n=352

Placebo Group

10%

10%

A Rui Si EVESS tablets 5-mg Group

18%*

18%*

A Rui Si EVESS tablets 10-mg Group

21%*

22%**

*p<0.05

**p<0.01

A Rui Si EVESS produced a dose-dependent statistically significant increase in the percentage of patients who were judged treatment responders.

The pharmacotherapeutic group: anti-dementia drugs; anticholinesterase; ATC-code N06DA02.

A Rui Si is a specific and reversible inhibitor of acetylcholinesterase, the predominant cholinesterase in the brain. A Rui Si is in vitro over 1000 times more potent an inhibitor of this enzyme than of butyrylcholinesterase, an enzyme that is present mainly outside the central nervous system.

Alzheimer's Dementia

In patients with Alzheimer's Dementia participating in clinical trials, administration of single daily doses of 5 mg or 10 mg of Donepezil produced steady-state inhibition of acetylcholinesterase activity (measured in erythrocyte membranes) of 63.6% and 77.3%, respectively when measured post dose. The inhibition of acetylcholinesterase (AChE) in red blood cells by A Rui Si has been shown to correlate to changes in ADAS-cog, a sensitive scale which examines selected aspects of cognition. The potential for A Rui Si to alter the course of the underlying neuropathology has not been studied. Thus Donepezil can not be considered to have any effect on the progress of the disease.

Efficacy of treatment with Donepezil has been investigated in four placebo-controlled trials, 2 trials of 6-month duration and 2 trials of 1-year duration.

In the 6 months clinical trial, an analysis was done at the conclusion of donepezil treatment using a combination of three efficacy criteria: the ADAS-Cog (a measure of cognitive performance), the Clinician Interview Based Impression of Change with Caregiver Input (a measure of global function) and the Activities of Daily Living Subscale of the Clinical Dementia Rating Scale ( a measure of capabilities in community affairs, home and hobbies and personal care).

Patients who fulfilled the criteria listed below were considered treatment responders.

Response = Improvement of ADAS-Cog of at least 4 points

No deterioration of CIBIC +

No Deterioration of Activities of Daily Living Subscale of the Clinical Dementia Rating Scale

% Response

Intent to Treat Population

n = 365

Evaluable Population

n = 352

Placebo group

10%

10%

A Rui Si 5 mg group

18%*

18%*

A Rui Si 10 mg group

21%*

22%**

* p<0.05

** p<0.01

Donepezil produced a dose-dependent statistically significant increase in the percentage of patients who were judged treatment responders.

Pharmacokinetic properties
The information provided in Pharmacokinetic properties of A Rui Si is based on data of another medicine with exactly the same composition as the A Rui Si of the medicine (Donepezil). Be careful and be sure to specify the information on the section Pharmacokinetic properties in the instructions to the drug A Rui Si directly from the package or from the pharmacist at the pharmacy.
more... close
Coated tablet; Film-coated tablet; Orodispersible tablet
Substance-powder

Absorption

Maximum plasma levels are reached approximately 3 to 4 hours after oral administration. Plasma concentrations and area under the curve rise in proportion to the dose. The terminal disposition half-life is approximately 70 hours, thus, administration of multiple single-daily doses results in gradual approach to steady-state. Approximate steady-state is achieved within 3 weeks after initiation of therapy. Once at steady-state, plasma donepezil hydrochloride concentrations and the related pharmacodynamic activity show little variability over the course of the day.

Food did not affect the absorption of donepezil hydrochloride.

Distribution

Donepezil hydrochloride is approximately 95% bound to human plasma proteins. The plasma protein binding of the active metabolite 6-O-desmethyl donepezil is not known. The distribution of donepezil hydrochloride in various body tissues has not been definitively studied. However, in a mass balance study conducted in healthy male volunteers, 240 hours after the administration of a single 5 mg dose of 14C-labelled donepezil hydrochloride, approximately 28% of the label remained unrecovered. This suggests that donepezil hydrochloride and/or its metabolites may persist in the body for more than 10 days.

Biotransformation/ Elimination

Donepezil hydrochloride is both excreted in the urine intact and metabolised by the cytochrome P450 system to multiple metabolites, not all of which have been identified. Following administration of a single 5 mg dose of 14C-labelled donepezil hydrochloride, plasma radioactivity, expressed as a percent of the administered dose, was present primarily as intact donepezil hydrochloride (30%), 6-O-desmethyl donepezil (11% – only metabolite that exhibits activity similar to donepezil hydrochloride), donepezil-cis-N-oxide (9%), 5-O-desmethyl donepezil (7%) and the glucuronide conjugate of 5-O-desmethyl donepezil (3%). Approximately 57% of the total administered radioactivity was recovered from the urine (17% as unchanged donepezil), and 14.5% was recovered from the faeces, suggesting biotransformation and urinary excretion as the primary routes of elimination. There is no evidence to suggest enterohepatic recirculation of donepezil hydrochloride and/or any of its metabolites.

Plasma donepezil concentrations decline with a half-life of approximately 70 hours.

Sex, race and smoking history have no clinically significant influence on plasma concentrations of donepezil hydrochloride. The pharmacokinetics of donepezil has not been formally studied in healthy elderly subjects or in Alzheimer's or vascular dementia patients. However mean plasma levels in patients closely agreed with those of young healthy volunteers.

Patients with mild to moderate hepatic impairment had increased donepezil steady state concentrations; mean AUC by 48% and mean Cmax by 39% .

Absorption: Maximum plasma levels are reached approximately 3 to 4 hours after oral administration. Plasma concentrations and area under the curve rise in proportion to the dose. The terminal disposition half-life is approximately 70 hours, thus, administration of multiple single-daily doses results in gradual approach to steady-state. Approximate steady-state is achieved within 3 weeks after initiation of therapy. Once at steady-state, plasma A Rui Si concentrations and the related pharmacodynamic activity show little variability over the course of the day.

Food did not affect the absorption of A Rui Si.

Distribution: A Rui Si is approximately 95% bound to human plasma proteins. The plasma protein binding of the active metabolite 6-O-desmethyldonepezil is not known. The distribution of A Rui Si in various body tissues has not been definitively studied. However, in a mass balance study conducted in healthy male volunteers, 240 hours after the administration of a single 5 mg dose of 14C-labeled A Rui Si, approximately 28% of the label remained unrecovered. This suggests that A Rui Si and/or its metabolites may persist in the body for more than 10 days.

Metabolism/Excretion: A Rui Si is both excreted in the urine intact and metabolised by the cytochrome P450 system to multiple metabolites, not all of which have been identified. Following administration of a single 5 mg dose of 14C-labeled A Rui Si, plasma radioactivity, expressed as a percent of the administered dose, was present primarily as intact A Rui Si (30%), 6-O-desmethyl donepezil (11% - only metabolite that exhibits activity similar to A Rui Si), donepezil-cis-N-oxide (9%), 5-O-desmethyl donepezil (7%) and the glucuronide conjugate of 5-O-desmethyl donepezil (3%). Approximately 57% of the total administered radioactivity was recovered from the urine (17% as unchanged donepezil), and 14.5% was recovered from the faeces, suggesting biotransformation and urinary excretion as the primary routes of elimination. There is no evidence to suggest enterohepatic recirculation of A Rui Si and/or any of its metabolites.

Plasma donepezil concentrations decline with a half-life of approximately 70 hours.

Sex, race and smoking history have no clinically significant influence on plasma concentrations of A Rui Si. The pharmacokinetics of donepezil has not been formally studied in healthy elderly subjects or in Alzheimer's or vascular dementia patients. However mean plasma levels in patients closely agreed with those of young healthy volunteers.

Patients with mild to moderate hepatic impairment had increased donepezil steady state concentrations; mean AUC by 48% and mean Cmax by 39% .

Pharmacotherapeutic group
The information provided in Pharmacotherapeutic group of A Rui Si is based on data of another medicine with exactly the same composition as the A Rui Si of the medicine (Donepezil). Be careful and be sure to specify the information on the section Pharmacotherapeutic group in the instructions to the drug A Rui Si directly from the package or from the pharmacist at the pharmacy.
more... close
anti-dementia drugs; anticholinesterase; ATC-code N06DA02.
Preclinical safety data
The information provided in Preclinical safety data of A Rui Si is based on data of another medicine with exactly the same composition as the A Rui Si of the medicine (Donepezil). Be careful and be sure to specify the information on the section Preclinical safety data in the instructions to the drug A Rui Si directly from the package or from the pharmacist at the pharmacy.
more... close
Coated tablet; Film-coated tablet; Orodispersible tablet
Substance-powder

Extensive testing in experimental animals has demonstrated that this compound causes few effects other than the intended pharmacological effects consistent with its action as a cholinergic stimulator . Donepezil is not mutagenic in bacterial and mammalian cell mutation assays. Some clastogenic effects were observed in vitro at concentrations overtly toxic to the cells and more than 3000 times the steady-state plasma concentrations. No clastogenic or other genotoxic effects were observed in the mouse micronucleus model in vivo. There was no evidence of oncogenic potential in long-term carcinogenicity studies in either rats or mice.

Donepezil hydrochloride had no effect on fertility in rats, and was not teratogenic in rats or rabbits, but had a slight effect on still-births and early pup survival when administered to pregnant rats at 50 times the human dose .

Extensive testing in experimental animals has demonstrated that this compound causes few effects other than the intended pharmacological effects consistent with its action as a cholinergic stimulator . Donepezil is not mutagenic in bacterial and mammalian cell mutation assays. Some clastogenic effects were observed in vitro at concentrations overtly toxic to the cells and more than 3000 times the steady-state plasma concentrations. No clastogenic or other genotoxic effects were observed in the mouse micronucleus model in vivo. There was no evidence of oncogenic potential in long term carcinogenicity studies in either rats or mice.

A Rui Si had no effect on fertility in rats, and was not teratogenic in rats or rabbits, but had a slight effect on still births and early pup survival when administered to pregnant rats at 50 times the human dose .

Incompatibilities
The information provided in Incompatibilities of A Rui Si is based on data of another medicine with exactly the same composition as the A Rui Si of the medicine (Donepezil). Be careful and be sure to specify the information on the section Incompatibilities in the instructions to the drug A Rui Si directly from the package or from the pharmacist at the pharmacy.
more... close
Coated tablet; Film-coated tablet; Orodispersible tablet
Substance-powder

Not applicable.

Not applicable

Special precautions for disposal and other handling
The information provided in Special precautions for disposal and other handling of A Rui Si is based on data of another medicine with exactly the same composition as the A Rui Si of the medicine (Donepezil). Be careful and be sure to specify the information on the section Special precautions for disposal and other handling in the instructions to the drug A Rui Si directly from the package or from the pharmacist at the pharmacy.
more... close
Coated tablet; Film-coated tablet; Orodispersible tablet
Substance-powder

No special requirements.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Available in countries
See all
close